A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu
A phase 1/2 trial of Obinutuzumab, Glofitamab, Rituximab in hodgkin lymphoma and non-hodgkin lymphoma, run by Hoffmann-La Roche, now recruiting.
Overview
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT05533775 by Hoffmann-La Roche, with 65 participants planned, started 2022-11-16 and due to reach its primary completion in 2029-11-30. Interventions recorded: Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin. Conditions listed: Mature B-Cell Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell
Shares Ifosfamide, Etoposide, Rituximab, Non-Hodgkin lymphoma (all types).
- TrialA Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat
Shares Glofitamab, Obinutuzumab, Roche / Genentech, Non-Hodgkin lymphoma (all types).
- TrialA Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Shares Glofitamab, Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
- TrialA Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi
Shares Glofitamab, Obinutuzumab, Roche / Genentech, Non-Hodgkin lymphoma (all types).
- TrialA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Shares Glofitamab, Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
- TrialEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Shares Glofitamab, Obinutuzumab, Hodgkin lymphoma.
- TrialA Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Shares Rituximab, Roche / Genentech, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialA Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Shares Glofitamab, Obinutuzumab, Non-Hodgkin lymphoma (all types).